$PMVP

PMV Pharmaceuticals reported a Q3 2026 net loss of $34.4M, with $108.5M in cash. It expects cash to last into Q1 2028. The company completed enrollment for its Phase 2 ovarian cancer trial and plans to submit a rezatapopt NDA in Q1 2027. Research and development expenses were $16.1M, with general and administrative expenses at $4.0M. The company appointed new board members and a chief commercial officer.

PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights • Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026 • Announced closing of oversubscribed $50 million public offering of sec

PMV Pharmaceuticals (PMVP) appointed Matt Eckler, Ph.D., to its Board of Directors. Dr. Eckler has over 20 years of experience in healthcare investing and research. The company plans to submit a New Drug Application for accelerated approval of rezatapopt, its treatment for platinum-resistant/refractory ovarian cancer, in Q1 2027.

Kodiak Sciences (KOD) rose 3% to $104 after positive Phase 3 trial results. 908 Devices (MASS) hit $12.93 with Q2 revenue up 23%. Orchestra BioMed (OBIO) reached $6.20, expanding Q2 loss by 23%. CareDx (CDNA) hit a 52-week high with Q2 revenue up 52%. PMV Pharmaceuticals (PMVP) rose 4% to $1.91 on positive clinical data.

PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 PMV Pharma Announces Pricing of Oversubscribed $50Million Public Offering of Securities PRINCETON, N.J. , August 31, 2026 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery

PMV Pharmaceuticals (Nasdaq: PMVP) reported Q2 2026 results and clinical updates. Enrollment for the Phase 2 monotherapy primary analysis in its PYNNACLE trial for rezatapopt in TP53 Y220C ovarian cancer is complete. The company plans an NDA for accelerated approval in Q1 2027. Cash, cash equivalents and marketable securities were $79.4M at June 30, 2026, with net loss $18.1M.

PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed • Rez

PMV Pharmaceuticals is entering a crucial first quarter of 2026 with several key events for its lead cancer therapy, rezatapopt. Investors are focused on upcoming financial results, a presentation at the TD Cowen Health Care Conference, and the critical completion of patient enrollment for its platinum-resistant ovarian cancer study. Meeting the enrollment target by late March 2026 is essential for the company's planned New Drug Application submission by Q1 2027.

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma

PRINCETON, N.J., Oct. 24, 2025 ( GLOBE NEWSWIRE ) -- PMV Pharmaceuticals, Inc. ( "PMV Pharma" or the "Company". Nasdaq: PMVP ) , a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced updated data from the ...